ArticleCureus2025
Weekly Versus Three-Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2 Negative, Stage III Breast Cancer: A Comparison of Treatment Responses.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity.Frontiers in cellular and infection microbiology · 2026Article
- Recurrent Hormone Receptor-Positive Breast Cancer With Multiple Sites of Distant Metastasis: A Case Report and Review of the Literature.International journal of breast cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimNeoadjuvant chemotherapy with doxorubicin (A) and cyclophosphamide (C) followed by taxane (T) (AC followed by T) is one of the standard regimens in locoregionally advanced breast cancer. Paclitaxel, a taxane, can be given either in a three-weekly or a weekly schedule. The aim of this study was to compare the efficacy in terms of the clinical and pathological response of three-weekly paclitaxel with weekly paclitaxel in the treatment of human epidermal growth factor receptor 2 (HER2)-negative, stage III breast cancer. MATERIALS AND
methodsA quasi-experimental study was conducted from April 2022 to October 2023 in two centers in Dhaka, Bangladesh. Sixty-six patients were enrolled and divided equally into two arms. Arm-A patients received four cycles of AC followed by paclitaxel (175 mg/m OBSERVATIONS AND
resultsPathological complete response (pCR) was achieved in 15 (25%) patients. Four patients (13.33%) in Arm A and 11 patients (36.66%) in Arm B had pCR. The difference was statistically significant (p 0.037). The p-value was 0.219 for response at the primary site and 0.13 for response in axillary disease. In both arms, patients with triple-negative receptor status had increased pCR (22.22% or two patients out of nine in Arm A, and 85.71% or six patients out of seven in Arm B) in comparison to hormone receptor (estrogen receptor (ER) and/or progesterone receptor (PR)) positive tumors (9.52% or two patients out of 21 in Arm A, and 21.74% or five patients out of 23 in Arm B). However, these differences were not significant.
conclusionAfter three-weekly administrations of four cycles of AC, the weekly administration of paclitaxel was found to be more effective in comparison to three-weekly administration of paclitaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.